Bank Of New York Mellon Corp Nymox Pharmaceutical Corp Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	BUY	$2.22 - $3.39 $4,386 - $6,698	1,976 Added 1.95%	103,404 $229,000
Q4 2020 Feb 09, 2021	BUY	$1.84 - $2.83 $20,687 - $31,817	11,243 Added 12.47%	101,428 $251,000
Q3 2020 Nov 12, 2020	BUY	$2.3 - $3.66 $804 - $1,281	350 Added 0.39%	90,185 $221,000
Q2 2020 Aug 12, 2020	BUY	$2.1 - $4.6 $188,653 - $413,240	89,835 New	89,835 $318,000
Q2 2019 Aug 12, 2019	SELL	$1.33 - $2.12 $99,428 - $158,486	-74,758 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$1.57 - $2.71 $5,173 - $8,929	3,295 Added 4.61%	74,758 $147,000
Q3 2018 Nov 09, 2018	SELL	$2.46 - $3.7 $2 - $3	-1 Reduced -0.0%	71,463 $0
Q2 2018 Aug 06, 2018	BUY	$3.12 - $4.33 $3,035 - $4,213	973 Added 1.38%	71,464 $240,000
Q4 2017 Feb 09, 2018	BUY	$3.29 - $4.06 $231,915 - $286,193	70,491	70,491 $233,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.